ArticleCellular oncology (Dordrecht, Netherlands)2026

A combined strategy of EGFR-MET bispecific antibody and HER3 ADC to overcome osimertinib resistance in NSCLC.

Yuanyuan Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.